Study participant demographics
| ID . | Age . | Gender . | Diagnosis . | Induction . | CMV (D/R) . | Experiments . |
|---|---|---|---|---|---|---|
| P1 | 40 | F | Cystic Fibrosis | Alemtuzumab | −/− | SC, FC, BS |
| P2 | 50 | F | Systemic Sclerosis | Basiliximab | +/+ | FC |
| P3 | 21 | F | Primary OB | Basiliximab | +/− | SC |
| P4 | 62 | M | Primary OB | Basiliximab | +/− | FC |
| P5 | 65 | F | IPF | Alemtuzumab | +/− | FC |
| P6 | 64 | M | IPF | Alemtuzumab | +/+ | FC |
| P7 | 66 | F | Emphysema | Basiliximab | +/+ | FC |
| P8 | 52 | M | Systemic Sclerosis | Basiliximab | +/− | SC, IF, Bulk, FC, BS |
| P9 | 70 | F | Emphysema | Alemtuzumab | +/+ | IF |
| P10 | 69 | M | IPF | Alemtuzumab | +/+ | FC |
| P11 | 67 | M | Emphysema | Alemtuzumab | −/− | FC |
| P12 | 31 | M | Cystic Fibrosis | Basiliximab | +/− | IF |
| P13 | 54 | M | Silicosis | Alemtuzumab | −/+ | FC |
| P14 | 30 | M | GVHD | Basiliximab | −/+ | FC |
| P15 | 56 | M | Sarcoidosis | Alemtuzumab | −/− | FC |
| P16 | 56 | F | Emphysema | Basiliximab | +/− | IF |
| P17 | 30 | F | Cystic Fibrosis | Alemtuzumab | +/+ | IF |
| P18 | 62 | M | IPF | Alemtuzumab | +/+ | FC |
| P19 | 51 | F | Other ILD | Basiliximab | +/− | FC |
| P20 | 68 | M | IPF | Basiliximab | −/− | FC |
| P21 | 45 | F | Emphysema | Alemtuzumab | −/− | FC |
| P22 | 62 | M | Environmental | Basiliximab | +/− | FC |
| ID . | Age . | Gender . | Diagnosis . | Induction . | CMV (D/R) . | Experiments . |
|---|---|---|---|---|---|---|
| P1 | 40 | F | Cystic Fibrosis | Alemtuzumab | −/− | SC, FC, BS |
| P2 | 50 | F | Systemic Sclerosis | Basiliximab | +/+ | FC |
| P3 | 21 | F | Primary OB | Basiliximab | +/− | SC |
| P4 | 62 | M | Primary OB | Basiliximab | +/− | FC |
| P5 | 65 | F | IPF | Alemtuzumab | +/− | FC |
| P6 | 64 | M | IPF | Alemtuzumab | +/+ | FC |
| P7 | 66 | F | Emphysema | Basiliximab | +/+ | FC |
| P8 | 52 | M | Systemic Sclerosis | Basiliximab | +/− | SC, IF, Bulk, FC, BS |
| P9 | 70 | F | Emphysema | Alemtuzumab | +/+ | IF |
| P10 | 69 | M | IPF | Alemtuzumab | +/+ | FC |
| P11 | 67 | M | Emphysema | Alemtuzumab | −/− | FC |
| P12 | 31 | M | Cystic Fibrosis | Basiliximab | +/− | IF |
| P13 | 54 | M | Silicosis | Alemtuzumab | −/+ | FC |
| P14 | 30 | M | GVHD | Basiliximab | −/+ | FC |
| P15 | 56 | M | Sarcoidosis | Alemtuzumab | −/− | FC |
| P16 | 56 | F | Emphysema | Basiliximab | +/− | IF |
| P17 | 30 | F | Cystic Fibrosis | Alemtuzumab | +/+ | IF |
| P18 | 62 | M | IPF | Alemtuzumab | +/+ | FC |
| P19 | 51 | F | Other ILD | Basiliximab | +/− | FC |
| P20 | 68 | M | IPF | Basiliximab | −/− | FC |
| P21 | 45 | F | Emphysema | Alemtuzumab | −/− | FC |
| P22 | 62 | M | Environmental | Basiliximab | +/− | FC |
BS, BaseScope; Bulk, bulk TCR sequencing from PBMC; FC, flow cytometry; GVHD, graft versus host disease; IF, immunofluorescence imaging; IPF, idiopathic pulmonary fibrosis; OB, obstructive bronchiolitis; SC, single-cell RNA/TCR sequencing.